Industry

Ribbon Biolabs Establishes IP Portfolio with First Granted U.S. Patent Covering Fast, Cost-Effective, Long DNA Synthesis Technology

VIENNA, Austria–(BUSINESS WIRE)–Ribbon Biolabs, the DNA synthesis company, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent US 2020283756 A1, covering Ribbon Biolabs’ novel method for synthesizing a double stranded polynucleotide, also known as DNA, using a diverse library of oligonucleotides. The patent is the first of its submitted patent applications … [Read more…]

CN Bio Opens New Laboratory Facilities to Extend Organ-on-a-chip Contract Research Services Capabilities

State-of-the-art laboratories significantly expand project capacity to meet increasing market demand for Organ-on-a-Chip research services CAMBRIDGE, England–(BUSINESS WIRE)–CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the opening of new laboratory facilities at Cambridge Science Park, dedicated to its contract research services. The Company’s laboratory space … [Read more…]

Paragraf® Announces Innovate UK Biomedical Catalyst Grant Award to Develop the First Proof of Concept Graphene-based Diagnostic Test to Immediately Identify Patients Who Need an Antibiotic Treatment

The test will be the first in a pipeline of affordable, portable, easy-to-use, graphene-based IVD products, which will at least match the performance of the most advanced hospital laboratory, but at the point of care. CAMBRIDGESHIRE, England–(BUSINESS WIRE)–Paragraf, the first company in the world to deliver a scalable approach to graphene electronic device manufacturing, announces … [Read more…]

ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens

Approval broadens indication for Daiichi Sankyo and AstraZeneca’s ENHERTU across Europe to earlier use in HER2 positive metastatic breast cancer Based on groundbreaking DESTINY-Breast03 results in which ENHERTU demonstrated a 72% reduction in the risk of disease progression or death vs. trastuzumab emtansine (T-DM1) TOKYO & MUNICH, Germany–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: … [Read more…]

SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile

BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC’s inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile through a collaboration with the Pontificia Universidad Católica de Chile (PI Dr. Pablo González). Study results will … [Read more…]

A Game-Changer for Young Children with Femur Fractures

LOS ANGELES–(BUSINESS WIRE)–For decades, the treatment for a young child with a broken femur has been the same: a surgically placed spica cast, commonly known as a body cast. But now, thanks to a new study led by Children’s Hospital Los Angeles, the days of casting these injuries may soon be over. The study, led … [Read more…]

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo

Opzelura is the first and only FDA-approved product for repigmentation in nonsegmental vitiligo Phase 3 data supporting the approval show treatment with Opzelura resulted in improvements in facial and total body repigmentation Fifty-two week data demonstrate continued improvements in repigmentation with longer duration of treatment Investor conference call and webcast scheduled for July 19, 2022, … [Read more…]

Quantum-Si to Report Second Quarter 2022 Financial Results on August 8, 2022

GUILFORD, Conn.–(BUSINESS WIRE)–Jul. 18, 2022–Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first next generation single molecule protein sequencing, today announced that it will report financial results for the second quarter 2022 after market close on Monday, August 8, 2022. Company management will host a conference call to … [Read more…]

Labcorp Expands Automated Clinical Trial Kit Production Line at European Operations Center

Expansion Will Grow Service Area to More Than 70 Countries Throughout Europe, the Middle East and Africa BURLINGTON, N.C.–(BUSINESS WIRE)–Labcorp® (NYSE: LH), a leading global life sciences company, today announced an expansion of its automated clinical trial kit production line in Mechelen, Belgium. Once completed, expansion will allow for clinical trial test kits to be … [Read more…]